ᱩᱛᱱᱟ.ᱣ
ᱡᱤᱱᱤᱥ ᱠᱚ: ᱜᱞᱩᱠᱚᱡᱽ ᱧᱩᱛᱩᱢ
ᱢᱮᱥᱮᱡᱽ/ᱢᱤᱴᱚᱨᱥ: ᱵᱚᱠᱥᱤᱝ, ᱑᱐%
ᱠᱚᱯᱤᱨᱟᱭᱤᱴ: ᱠᱮᱯᱤᱴᱟᱞ, ᱠᱤᱵᱚᱨᱰ, ᱠᱮᱯᱤᱴᱟᱞ, ᱠᱮᱯᱤᱴᱟᱞ, ᱠᱮᱯᱤᱮ/ᱮᱭ, ᱵᱮᱝᱠᱤᱝ
ᱮᱢᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢᱮᱢ: ᱓᱕᱐ ᱢᱤᱢᱤᱢ/ᱢᱤᱴᱚᱨᱥ, ᱮᱢᱮᱢᱡᱤ/ᱮᱢᱮᱢ, ᱓᱕᱐ ᱢᱤᱢᱤᱢ, ᱜᱽᱨᱟᱢ, ᱰᱤ
ᱯᱷᱟᱨᱢᱟᱠᱳᱞᱳᱡᱤ ᱮᱥᱮᱨ ᱠᱚᱺ
ᱠᱚᱯᱤᱨᱟᱭᱤᱴ ᱫᱚ ᱱᱚᱶᱟ ᱠᱟᱱᱟ ᱡᱮ β ᱫᱚ β-ᱟᱢᱮᱨᱤᱠᱟᱱ ᱱᱮᱴᱣᱟᱨᱠ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱱᱚᱶᱟ ᱠᱚ ᱵᱚᱫᱚᱞ ᱞᱟᱹᱜᱤᱫ ᱵᱟᱝ ᱠᱟᱱᱟ: μg hirginosions ᱾
᱑. ᱡᱚᱢᱟᱜ ᱡᱤᱱᱤᱥ ᱠᱚ: ᱵᱟᱹᱲᱛᱤᱜ ᱠᱟᱱ ᱡᱚᱢᱟᱜ ᱠᱚ, ᱵᱟᱹᱲᱛᱤ ᱟᱨ ᱠᱚᱢ, ᱨᱟᱱ ᱠᱚ ᱨᱮᱭᱟᱜ ᱵᱮᱵᱷᱟᱨ᱾
2. ᱠᱟᱨᱵᱚᱦᱟᱭᱰᱨᱮᱴᱥ: ᱜᱞᱩᱠᱚᱡᱽ ᱨᱮᱭᱟᱜ ᱫᱟᱲᱮ ᱫᱚ ᱢᱤᱫ ᱚᱠᱛᱚ ᱨᱮ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱠᱚᱢᱡᱩᱨᱤ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱾
3.Synergistic effect (such as compound preparations) : When combined with GLP-1 receptor agonists (such as semaglutide), it can dual regulate metabolism and enhance weight loss and hypoglycemic effects.
ᱯᱨᱚᱰᱟᱠᱴᱤᱵᱷᱤᱴᱤ
HCV-2: α-CoV-1 (2.5%) ᱨᱮ ᱠᱚᱢ ᱥᱮ ᱠᱚᱢ 10% ᱠᱷᱚᱱ ᱠᱚᱢ ᱮᱥᱮᱨ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ ᱫᱚ ᱵᱷᱮᱜᱟᱨ ᱞᱮᱠᱟ ᱵᱩᱡᱷᱟᱹᱣ ᱟᱠᱟᱱᱟ᱾
ᱚᱡᱚᱱ ᱠᱚᱢ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ: ᱜᱡᱚᱴᱱᱟ ᱨᱮᱭᱟᱜ ᱜᱚᱲᱦᱚᱱ ᱫᱚ 2.5% (ᱪᱤᱛᱟᱹᱨ 25)=2.4% ᱨᱮ ᱧᱮᱞᱚᱜ ᱠᱟᱱᱟ ᱾
ᱪᱤᱠᱤᱥᱟᱱ: ᱠᱟᱨᱰᱤᱭᱚᱵᱟᱥᱠᱩᱞᱟᱨ ᱠᱟᱨᱟᱠ ᱠᱚ ᱨᱮᱭᱟᱜ ᱚᱨᱡᱚ ᱫᱚ ᱵᱟᱝ ᱵᱮᱥ ᱞᱮᱠᱟ ᱧᱮᱞᱚᱜ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱨᱩᱜᱤ ᱠᱚ ᱨᱮ ᱵᱟᱝ ᱵᱮᱥ ᱮᱥᱮᱨ ᱦᱩᱭ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾
ᱦᱚᱜᱽᱥ: 150 μm ᱨᱮᱭᱟᱜ ᱜᱩᱱ ᱫᱚ exposition ko hibode khable kạmi ko, hodio ar hable ko, hapophode khon khabode khab, hapap hoution ke ko, hable khabution lạgit̕ kạmi kha jạruṛ ge kạmi kha jạruṛ ge kạmi ko kạmi lạgit̕ kạmi ᱠᱟᱱᱟ᱾